Doxycycline and other tetracyclines in the treatment of bone metastasis

Anti-Cancer Drugs

Volumn 14, Issue 10, 2003, Pages 773-778

  Saikali, Zeina ^a   Singh, Gurmit ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Bone; Col 3; Doxycycline; Matrix metalloproteinases; Metastasis; Minocycline; Tetracycline

Indexed keywords

DOXYCYCLINE FOSFATEX; MATRIX METALLOPROTEINASE; MINOCYCLINE; TETRACYCLINE DERIVATIVE;

BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELL INVASION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; METASTASIS; MORBIDITY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SHORT SURVEY; TUMOR CELL;

EID: 1542510038     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200311000-00001     Document Type: Short Survey

References (56)

1. Smilack JD. The tetracyclines. Mayo Clin Proc 1999; 74:727-729.
2. Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003; CD002086.
3. Adimora AA. Treatment of uncomplicated genital Chlamydia trachomatis infections in adults. Clin Infect Dis 2002; 35:S183-S186.
4. Kovacova E, Kazar J. Q fever - still a query and underestimated infectious disease. Acta Virol 2002; 46:193-210.
5. Cunha BA. Clinical relevance of penicillin-resistant Streptococcus pneumoniae. Semin Respir Infect 2002; 17:204-214.
6. Clark JMJ, Chang AY. Inhibitors of the transfer of amino acids from aminoacyl soluble ribonucleic acid to proteins. J Biol Chem 1965; 240:4734-4739.
7. Kroon AM, Van den Bogert C. Antibacterial drugs and their interference with the biogenesis of mitochondria in animal and human cells. Pharm Weekbl Sci 1983; 5:81-87.
8. Kroon AM, Dontje BH, Holtrop M, Van den Bogert C. The mitochondrial genetic system as a target for chemotherapy: tetracyclines as cytostatics. Cancer Lett 1984; 25:33-40.
9. Van den Bogert C, Dontje BH, Kroon AM. The antitumour effect of doxycycline on a T-cell leukaemia in the rat. Leuk Res 1985; 9:617-623.
10. Van den Bogert C, Dontje BH, Holtrop M, Melis TE, Romijn JC, van Dongen JW, et al. Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. Cancer Res 1986; 46:3283-3289.
11. 1-phase of the cell cycle. Cancer Lett 1986; 32:41-51.
12. Duivenvoorden WC, Hirte HW, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 1997; 17:312-322.
13. Fife RS, Rougraff BT, Proctor C, Sledge GWJ. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 1997; 130:530-534.
14. Fife RS, Sledge GWJ, Roth BJ, Proctor C. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett 1998; 127:37-41.
15. Rubins JB, Charboneau D, Alter MD, Bitterman PB, Kratzke RA. Inhibition of mesothelioma cell growth in vitro by doxycycline. J Lab Clin Med 2001; 138:101-106.
16. Liu J, Kuszynski CA, Baxter BT. Doxycycline induces Fas/Fas ligand-mediated apoptosis in Jurkat T lymphocytes. Biochem Biophys Res Commun 1999; 260:562-567.
17. Tolomeo M, Grimaudo S, Milano S, La Rosa M, Ferlazzo V, Di Bella G, et al. Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. Br J Pharmacol 2001; 133:306-314.
18. Iwasaki H, Inoue H, Mitsuke Y, Badran A, Ikegaya S, Ueda T. Doxycycline induces apoptosis by way of caspase-3 activation with inhibition of matrix metalloproteinase in human T-lymphoblastic leukemia CCRF-CEM cells. J Lab Clin Med 2002; 140:382-386.
19. Healy DP, Silverman PA, Neely AN, Holder IA, Babcock GE. Effect of antibiotics on polymorphonuclear neutrophil apoptosis. Pharmacotherapy 2002; 22:578-585.
20. Tikka T, Usenius T, Tenhunen M, Keinanen R, Koistinaho J. Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic, protect neurons against apoptosis induced by ionizing radiation. J Neurochem 2001; 78:1409-1414.
21. Bettany JT, Wolowacz RG. Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells. Adv Dent Res 1998; 12:136-143.
22. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 1995; 170:69-74.
23. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg 1993; 55:1115-1121.
24. Wakai K, Ohmura E, Satoh T, Murakami H, Isozaki O, Emoto N, et al. Mechanism of inhibitory actions of minocycline and doxycycline on ascitic fluid production induced by mouse fibrosarcoma cells. Life Sci 1994; 54:703-709.
25. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983; 18:516-526.
26. Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, et al. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 1987; 14:28-32.
27. Fife RS, Sledge GWJ. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 1995; 125:407-411.
28. Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, et al. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 1996; 52:105-111.
29. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 1997; 272:31504-31509.
30. Cakir Y, Hahn KA. Direct action by doxycycline against canine osteosarcoma cell proliferation and collagenase (MMP-1) activity in vitro. In vivo 1999; 13:327-331.
31. Crout RJ, Lee HM, Schroeder K, Crout H, Ramamurthy NS, Wiener M, et al. The 'cyclic' regimen of low-dose doxycycline for adult periodontitis: a preliminary study. J Periodontol 1996; 67:506-514.
32. Golub LM, McNamara TF, Ryan ME, Kohut B, Blieden T, Payonk G, et al. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontol 2001; 28:146-156.
33. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99:157-166.
34. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193.
35. Fife RS, Sledge GWJ, Sissons S, Zerler B. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett 2000; 153:75-78.
36. Gordon MS, Battiato LA, Jones D, Roth B, Harrison-Mann B, Fife RS, et al. A phase I trial of doxycycline (Doxy) in patients with cancer. Proc Am Soc Clin Oncol 1997; 16:226-226.
37. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991; 2:297-321.
38. Lee HM, Golub LM, Cao J, Teronen O, Laitinen M, Salo T, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem 2001; 8:257-260.
39. Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem 2001; 8:261-270.
40. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002; 98:297-309.
41. Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001; 19:584-592.
42. Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, et al. Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. Am J Hematol 2001; 67:51-53.
43. Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, et al. Drug-induced lupus associated with COL-3: report of 3 cases. Arch Dermatol 2001; 137:471-474.
44. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20:153-159.
45. Li J, Huynh H, Chan E. Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharm Res 2002; 19:1655-1662.
46. Duivenvoorden WC, Lhotak S, Lee F, Tozer RG, Hirte HW, Singh G. Bone metastasis in human breast and prostate cancer: Involvement of matrix metalloproteinases. Recent Res Devel Cancer 2000; 2:115-141.
47. Sanchez-Sweatman OH, Lee J, Orr FW, Singh G. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer 1997; 33:918-925.
48. Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998; 18:297-305.
49. Williams S, Wakisaka A, Zeng QQ, Barnes J, Martin G, Wechter WJ, et al. Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 1996; 19:637-644.
50. Williams S, Wakisaka A, Zeng QQ, Barnes J, Seyedin S, Martin G, et al. Effect of minocycline on osteoporosis. Adv Dent Res 1998; 12:71-75.
51. Williams S, Barnes J, Wakisaka A, Ogasa H, Liang CT. Treatment of osteoporosis with MMP inhibitors. Ann NY Acad Sci 1999; 878:191-200.
52. Grevstad HJ, Boe OE. Effect of doxycycline on surgically induced osteoclast recruitment in the rat. Eur J Oral Sci 1995; 103:156-159.
53. Bezerra MM, Brito GA, Ribeiro RA, Rocha FA. Low-dose doxycycline prevents inflammatory bone resorption in rats. Braz J Med Biol Res 2002; 35:613-616.
54. Bettany JT, Peet NM, Wolowacz RG, Skerry TM, Grabowski PS. Tetracyclines induce apoptosis in osteoclasts. Bone 2000; 27:75-80.
55. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55:3551-3557.
56. Duivenvoorden WC, Popovic SV, Lhotak S, Seidlitz E, Hirte HW, Tozer RG, et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res 2002; 62:1588-1591.